



## Doherty Clinical Trials to host HERACLES trial

### Highlights

- **Contract signed with Doherty Clinical Trials**
- **Melbourne site capitalises on Australian knowhow**
- **Expert team with wide-ranging experience**

**Sydney, 12 March 2025:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce it has engaged a highly-regarded Australian Phase 1 Unit to deliver the upcoming [HERACLES clinical trial](#).

The trial will take place in Melbourne and will be conducted by [Doherty Clinical Trials Ltd](#), a specialist not-for-profit organisation established by the prestigious Peter Doherty Institute for Infection and Immunity.

The Doherty Clinical Trials team has wide-ranging experience working with some of the world's leading clinical investigators and research scientists, and has a particular focus on early phase studies. It is renowned for its deep clinical trial knowledge, as well as its experience in infectious diseases and, most importantly, immunology.

Doherty Clinical Trials CEO Dr Andrew Brockway said: "We are passionate about the development of new medicines for diseases with unmet medical needs and are excited to support Noxopharm through our extensive knowhow and network of collaborators."

Noxopharm CEO Dr Gisela Mautner said: "We are very pleased to have secured such an outstanding organisation to host the HERACLES trial. The Doherty Clinical Trials team are experts in what they do, and we are looking forward to working closely with them as we take our innovative SOF-SKN™ drug for lupus into the clinic for the first time."

Peter Doherty, the patron of the Doherty Institute, has been involved in research on infection and immunity for 50 years. He won the 1996 Nobel Prize in Physiology or Medicine for discovering how the immune system recognises virus-infected cells, and was named Australian of the Year in 1997.

**-ENDS-**

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).



Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.